Bahaa Al-Trad, Yazan Abu Haija, Alaa A Aljabali, Ghada Alomari, Lena Tahat, Muath Q Al-Ghadi
{"title":"The Effects of 1,8-Cineole Treatment on Benign Prostatic Hyperplasia in Rats.","authors":"Bahaa Al-Trad, Yazan Abu Haija, Alaa A Aljabali, Ghada Alomari, Lena Tahat, Muath Q Al-Ghadi","doi":"10.2174/0113892010356355241222215343","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Benign prostatic hyperplasia is a non-malignant growth of the prostate gland; it's the most common prostatic growth in aging men. 1,8-cineole is a natural compound that is extracted from the essential oil of several aromatic plants including Eucalyptus spp. Recent studies have demonstrated the anti-inflammatory, antioxidant, and anticancer activities of 1,8-cineole. This study aims to investigate the effects of 1,8-cineole treatment on the development of BPH induced by testosterone in rats.</p><p><strong>Method: </strong>Thirty adult male rats were divided into three groups (n=10): a control group, an untreated BPH group that received subcutaneous injections of testosterone (3 mg/kg), and a BPH+cineole group that received 50 mg/kg of cineole intraperitoneally in addition to testosterone for 21 days. Histological changes, serum testosterone, and dihydrotestosterone (DHT) levels, prostatic tissue content of the inflammatory biomarkers interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), oxidative stress biomarkers superoxide dismutase (SOD) and malondialdehyde (MDA), angiogenesis biomarker vascular endothelial growth factor (VEGF-A), cellular proliferation biomarker proliferating cell nuclear antigen (PCNA), transforming growth factor beta-1 (TGF-β1), and pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) genes were analyzed.</p><p><strong>Results: </strong>Cineole treatment led to a reduction in the prostate weight-to-body weight ratio, as well as the restoration of histopathological changes caused by testosterone. Cineole treatment reduced the serum levels of testosterone and DHT, and the prostatic tissue levels of IL-1β, TNF-α, VEGF-A, PCNA, and TGF-β1 compared to those in the BPH group. Additionally, cineole treatment enhanced the SOD activity and decreased the MDA levels in the prostate tissue. Finally, the mRNA expression of the Bax was increased, while the expression of the Bcl-2 was decreased by cineole.</p><p><strong>Conclusion: </strong>Our results highlight the effectiveness of cineole in preventing BPH development in rats. This preventive effect was attributed to the regulation of inflammatory responses, oxidative stress, cellular proliferation, and apoptosis.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010356355241222215343","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Benign prostatic hyperplasia is a non-malignant growth of the prostate gland; it's the most common prostatic growth in aging men. 1,8-cineole is a natural compound that is extracted from the essential oil of several aromatic plants including Eucalyptus spp. Recent studies have demonstrated the anti-inflammatory, antioxidant, and anticancer activities of 1,8-cineole. This study aims to investigate the effects of 1,8-cineole treatment on the development of BPH induced by testosterone in rats.
Method: Thirty adult male rats were divided into three groups (n=10): a control group, an untreated BPH group that received subcutaneous injections of testosterone (3 mg/kg), and a BPH+cineole group that received 50 mg/kg of cineole intraperitoneally in addition to testosterone for 21 days. Histological changes, serum testosterone, and dihydrotestosterone (DHT) levels, prostatic tissue content of the inflammatory biomarkers interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), oxidative stress biomarkers superoxide dismutase (SOD) and malondialdehyde (MDA), angiogenesis biomarker vascular endothelial growth factor (VEGF-A), cellular proliferation biomarker proliferating cell nuclear antigen (PCNA), transforming growth factor beta-1 (TGF-β1), and pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) genes were analyzed.
Results: Cineole treatment led to a reduction in the prostate weight-to-body weight ratio, as well as the restoration of histopathological changes caused by testosterone. Cineole treatment reduced the serum levels of testosterone and DHT, and the prostatic tissue levels of IL-1β, TNF-α, VEGF-A, PCNA, and TGF-β1 compared to those in the BPH group. Additionally, cineole treatment enhanced the SOD activity and decreased the MDA levels in the prostate tissue. Finally, the mRNA expression of the Bax was increased, while the expression of the Bcl-2 was decreased by cineole.
Conclusion: Our results highlight the effectiveness of cineole in preventing BPH development in rats. This preventive effect was attributed to the regulation of inflammatory responses, oxidative stress, cellular proliferation, and apoptosis.
期刊介绍：
Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include:
DNA/protein engineering and processing
Synthetic biotechnology
Omics (genomics, proteomics, metabolomics and systems biology)
Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes)
Drug delivery and targeting
Nanobiotechnology
Molecular pharmaceutics and molecular pharmacology
Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes)
Pharmacokinetics and pharmacodynamics
Applied Microbiology
Bioinformatics (computational biopharmaceutics and modeling)
Environmental biotechnology
Regenerative medicine (stem cells, tissue engineering and biomaterials)
Translational immunology (cell therapies, antibody engineering, xenotransplantation)
Industrial bioprocesses for drug production and development
Biosafety
Biotech ethics
Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.
Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
